Internet Pioneer In...
Health Care: Drugs
Compugen Ltd. (CGEN: NASDAQ)
$3.41 -0.12 | -3.40%
06/01/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 0.00 | 1.12M | 250.00K | 338.00K |
| Cost of Sales | -179.00K | 23.00K | -250.00K | -501.00K |
| Gross Operating Profit | 179.00K | 1.09M | 500.00K | 839.00K |
| Selling, General, and Administrative Expenses | 5.20M | 3.54M | 2.83M | 4.50M |
| Research & Development | 6.78M | 5.23M | 5.05M | 8.74M |
| Operating Income before D & A (EBITDA) | -11.80M | -7.68M | -7.38M | -12.40M |
| Depreciation & Amortization | 179.00K | 201.00K | 250.00K | 508.00K |
| Interest Income | 421.00K | 241.00K | 65.00K | 502.00K |
| Other Income - Net | 281.00K | 434.00K | 3.72M | 53.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -11.28M | -7.20M | -3.84M | -12.36M |
| Interest Expense | 727.00K | 0.00 | 0.00 | 154.00K |
| Pre-Tax Income | -12.00M | -7.20M | -3.84M | -12.51M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -12.00M | -7.20M | -3.84M | -12.51M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 12.00K | -16.00K |
| Net Income From Total Operations | -12.00M | -7.20M | -3.83M | -12.53M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -12.00M | -7.20M | -3.83M | -12.53M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-12.00M | -7.20M | -3.84M | -12.51M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -12.00M | -7.20M | -3.84M | -12.51M |
| Basic EPS from Continuing Ops. | -0.35 | -0.22 | -0.13 | -0.44 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.35 | -0.22 | -0.13 | -0.44 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.35 | -0.22 | -0.13 | -0.44 |
| Basic Normalized Net Income/Share | -0.35 | -0.22 | -0.13 | -0.44 |
| EPS fr Continuing Ops. | -0.35 | -0.22 | -0.13 | -0.44 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.35 | -0.22 | -0.13 | -0.44 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.35 | -0.22 | -0.13 | -0.44 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.35 | -0.22 | -0.13 | -0.44 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CGEN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Bargain Biotech Stocks
- Userdesignbydiana Portfolio 1
- Userraveha1 Portfolio 1
- ContributorBiotech Short Squeezes
- UserSUPRATRADE-QUANTUM STARDUST 8
- UserHumelor Portfolio 1
Latest CGEN Headlines from TheStreet
- 7 Stocks Under $10 Soaring Higher 05.24.12 | 12:05 pm
- 5 Bargain Biotech Stocks 01.13.11 | 05:01 pm
- Maguire Properties, Compugen: Midday Volume Plays 05.11.10 | 11:05 am
- eOn Communications, Compugen: Early Volume Plays 03.16.10 | 09:03 am
- Pluristem Therapeutics, Compugen: Early Volume Plays 03.02.10 | 09:03 am
- Array BioPharma, Sterling Financial: Early Volume Plays 02.02.10 | 09:02 am
- Biotech's Movers & Shakers 2009: BioBuzz 01.04.10 | 09:01 am
- Compugen, Flotek: Early Volume Plays 01.04.10 | 07:01 am
- China BAK, Compugen: Early Volume Plays 12.30.09 | 08:12 am
- Compugen, Sinovac: Early Volume Plays 12.28.09 | 08:12 am
Press Releases for CGEN
- Dr. Mary Haak-Frendscho, Chairperson Of Compugen’s US Subsidiary, To Give Keynote Address At China Pharmaceutical R&D Summit - Business Wire 04.23.12 | 07:04 am
- Compugen First Quarter 2012 Conference Call Scheduled For Tuesday, May 1, 2012 At 10:00 AM EST - Business Wire 04.23.12 | 07:04 am
- Compugen Presents Prediction Based Discovery Strategy At “Targets And Strategies For Drug Discovery” Conference - Business Wire 02.27.12 | 07:02 am
- Compugen Cancer Target Results Demonstrate Significant Potential For Cancer Immunotherapy - Business Wire 02.02.12 | 06:02 am
- Compugen To Broaden And Accelerate Monoclonal Antibody Program For Oncology And Immunology - Business Wire 12.20.11 | 10:12 am
- BioLineRx To Develop And Commercialize Novel Peptide Drug Candidates Discovered By Compugen - Business Wire 12.13.11 | 06:12 am
- Compugen Presents Predictive Drug Target Discovery Platform At European Antibody Conference - Business Wire 11.30.11 | 07:11 am
- Www.discoverx.com - Business Wire 11.29.11 | 07:11 am
- Compugen Reports Third Quarter 2011 Financial Results - Business Wire 11.08.11 | 07:11 am
- Compugen's CGEN-15001 Pre-Clinical Data Presented At International Conference On Immune Tolerance - Business Wire 10.25.11 | 07:10 am
Partner Headlines for CGEN
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- Compugen: On the Road to Breakthroughs - Seeking Alpha 05.12.10 | 03:05 am
